“…Moreover, a baseline NLR is a promising prognostic biomarker for treatment response in melanoma patients receiving immunotherapy, and also, an agnostic, modality-independent predictive factor of shortened overall survival and progression-free survival in metastatic melanoma, treated with either metastasectomy or immunotherapies. Review papers and meta-analysis studies have compiled the pertinent data on this growing body of evidence [ 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ] and will not be reviewed again herein. Herewith, to supplement the evidence of the use of the NLR (and allied hematological biomarkers) in cutaneous oncology, we aim to systematically review, and consequently summarize the evidence on, their application in assessing prognosis, survival, and treatment outcomes in patients with skin malignancies other than malignant melanoma.…”